









Mercado
/
Acciones
/
nasdaq-ardx
/

Ardelyx Inc

ARDX

4.390USD

+0.060+1.39%

Horarios del mercado （ET）Cotizaciones retrasadas 15 min

1.05BCap. mercado

PérdidaP/E TTM



Ardelyx Inc

4.390

+0.060+1.39%

Descripción general Compañía Finanzas

Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

Información de la empresa

Símbolo de cotizaciónARDX

Nombre de la empresaArdelyx Inc

Fecha de salida a bolsaJun 19, 2014

Director ejecutivoMr. Michael G. (Mike) Raab

Número de empleados395

Tipo de seguridadOrdinary Share

Fin del año fiscalJun 19

Dirección400 Fifth Avenue

CiudadWALTHAM

Bolsa de valoresNASDAQ Global Market Consolidated

PaísUnited States of America

Código postal02451

Teléfono15107451700

Sitio Webhttps://www.ardelyx.com/

Símbolo de cotizaciónARDX

Fecha de salida a bolsaJun 19, 2014

Director ejecutivoMr. Michael G. (Mike) Raab

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. David M. (Dave) Mott

Independent Chairman of the Board

2.86M

+19.80%

Mr. Michael G. (Mike) Raab

President, Chief Executive Officer, Director

477.14K

-12.42%

Mr. Richard J. (Rick) Rodgers

Independent Director

413.54K

+17.98%

Mr. Eric Foster

Chief Commercial Officer

314.17K

-0.79%

Ms. Muna Bhanji

Independent Director

137.35K

+43.37%

Mr. Robert B. (Rob) Bazemore, Jr.

Independent Director

41.55K

James Brady

Chief Human Resources Officer

Dr. Merdad Parsey, M.D., Ph.D.

Independent Director

Mr. Mike Kelliher

Chief Business Officer

Mr. William C. (Bill) Bertrand, Jr., Esq.

Independent Director

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. David M. (Dave) Mott

Independent Chairman of the Board

2.86M

+19.80%

Mr. Michael G. (Mike) Raab

President, Chief Executive Officer, Director

477.14K

-12.42%

Mr. Richard J. (Rick) Rodgers

Independent Director

413.54K

+17.98%

Mr. Eric Foster

Chief Commercial Officer

314.17K

-0.79%

Ms. Muna Bhanji

Independent Director

137.35K

+43.37%

Mr. Robert B. (Rob) Bazemore, Jr.

Independent Director

41.55K

Desglose de ingresos

FY2025Q1

FY2024

FY2024Q2

FY2024Q1

Por negocioUSD

Nombre

Ganancia

Proporción

IBSRELA

44.40M

0.00%

XPHOZAH

23.41M

0.00%

Sin datos

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

IBSRELA

44.40M

0.00%

XPHOZAH

23.41M

0.00%

Estadísticas de accionistas

Actualizado: sáb., 17 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

Janus Henderson Investors

10.44%

The Vanguard Group, Inc.

6.70%

BlackRock Institutional Trust Company, N.A.

6.64%

Millennium Management LLC

5.06%

Macquarie Investment Management

4.66%

Other

66.50%

Accionistas

Proporción

Janus Henderson Investors

10.44%

The Vanguard Group, Inc.

6.70%

BlackRock Institutional Trust Company, N.A.

6.64%

Millennium Management LLC

5.06%

Macquarie Investment Management

4.66%

Other

66.50%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

27.48%

Investment Advisor/Hedge Fund

26.34%

Hedge Fund

13.49%

Research Firm

4.93%

Individual Investor

2.66%

Bank and Trust

0.37%

Pension Fund

0.36%

Family Office

0.09%

Insurance Company

0.03%

Other

24.24%

Participación institucional

Actualizado: mar., 1 de jul

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q2

460

181.09M

75.69%

+6.96M

2025Q1

470

173.66M

72.61%

+2.64M

2024Q4

452

158.29M

66.42%

-9.57M

2024Q3

441

149.04M

63.31%

-41.81M

2024Q2

420

152.02M

64.97%

-36.87M

2024Q1

399

149.36M

64.27%

-40.02M

2023Q4

363

143.31M

61.82%

-29.22M

2023Q3

347

131.10M

60.21%

-55.04M

2023Q2

355

129.77M

60.57%

-68.74M

2023Q1

359

119.15M

57.99%

-45.93M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Janus Henderson Investors

24.98M

10.44%

+589.07K

+2.42%

Mar 31, 2025

The Vanguard Group, Inc.

14.94M

6.25%

+634.58K

+4.44%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

15.88M

6.64%

-651.24K

-3.94%

Mar 31, 2025

Millennium Management LLC

12.10M

5.06%

+5.63M

+87.15%

Jun 17, 2025

Macquarie Investment Management

11.16M

4.66%

+811.55K

+7.84%

Mar 31, 2025

State Street Global Advisors (US)

10.18M

4.25%

-1.42M

-12.22%

Mar 31, 2025

Marshall Wace LLP

8.38M

3.5%

+8.27M

+7201.76%

Mar 31, 2025

Geode Capital Management, L.L.C.

5.67M

2.37%

+162.88K

+2.96%

Mar 31, 2025

Nuveen LLC

3.39M

1.42%

+1.24M

+57.47%

Mar 31, 2025

Citadel Advisors LLC

3.19M

1.33%

+699.74K

+28.09%

Mar 31, 2025

ETFs relacionados

Actualizado: sáb., 2 de ago

Nombre

Proporción

Virtus LifeSci Biotech Products ETF

2.03%

Harbor Human Capital Factor US Small Cap ETF

0.53%

Invesco NASDAQ Future Gen 200 ETF

0.48%

SPDR S&P Biotech ETF

0.36%

Direxion Daily S&P Biotech Bull 3X Shares

0.2%

First Trust Small Cap Growth AlphaDEX Fund

0.18%

Inspire Small/Mid Cap ESG ETF

0.16%

Invesco Nasdaq Biotechnology ETF

0.1%

ProShares Ultra Nasdaq Biotechnology

0.1%

iShares Russell 2000 Growth ETF

0.06%

Virtus LifeSci Biotech Products ETF

Proporción2.03%

Harbor Human Capital Factor US Small Cap ETF

Proporción0.53%

Invesco NASDAQ Future Gen 200 ETF

Proporción0.48%

SPDR S&P Biotech ETF

Proporción0.36%

Direxion Daily S&P Biotech Bull 3X Shares

Proporción0.2%

First Trust Small Cap Growth AlphaDEX Fund

Proporción0.18%

Inspire Small/Mid Cap ESG ETF

Proporción0.16%

Invesco Nasdaq Biotechnology ETF

Proporción0.1%

ProShares Ultra Nasdaq Biotechnology

Proporción0.1%

iShares Russell 2000 Growth ETF

Proporción0.06%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones

Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos

KeyAI

